Clinical data | |
---|---|
Other names | 4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(dimethylcarbamate) |
Routes of administration | By mouth [1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~35% (in mice) [2] |
Metabolites | Tropoflavin [1] |
Elimination half-life | ~3.25 hours (in mice [2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C21H20N2O6 |
Molar mass | 396.399 g·mol−1 |
3D model ( JSmol) | |
| |
|
R7 is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB) – the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF) – which is under development for the treatment of Alzheimer's disease. [1] [3] [2] It is a structural modification and prodrug of tropoflavin (7,8-DHF) with improved potency and pharmacokinetics, namely oral bioavailability and duration. [2]
R7 was synthesized by the same researchers who were involved in the discovery of tropoflavin. [2] [4] A patent was filed for R7 in 2013 and was published in 2015. [2] In 2016, it was reported to be in the preclinical stage of development. [1] [3] R7 was superseded by R13 because while R7 had a good drug profile in animals, it showed almost no conversion into tropoflavin in human liver microsomes. [5]
Tropoflavin, a naturally occurring flavonoid, was found to act as an agonist of the TrkB with nanomolar affinity (Kd ≈ 320 nM). [4]
Due to the presence of a vulnerable catechol group on its 2- phenyl-4H- chromene ring, tropoflavin is extensively conjugated via glucuronidation, sulfation, and methylation during first-pass metabolism in the liver and has a poor oral bioavailability of only 5% in mice upon oral administration. [2] As such, tropoflavin itself is a poor candidate for clinical development as an oral medication. [2] R7 is a derivative of tropoflavin with carbamate moieties on its hydroxyl groups, thereby protecting it from metabolism. [2]
As R7 is a slightly larger molecule than tropoflavin, 72.5 mg R7 is molecularly equivalent to 50 mg tropoflavin. [2] Relative to a roughly molecularly equivalent dose of tropoflavin, the area-under-curve levels of R7 were found to be 7.2-fold higher upon oral administration to mice, and R7 hence has a greatly improved oral bioavailability in mice of approximately 35%. [2] Moreover, whereas tropoflavin itself is mostly metabolized in mice within 30 minutes, tropoflavin as a metabolite was still detectable in plasma at 8 hours after administration with R7, indicating that R7 sustainably releases tropoflavin into circulation. [2] In accordance, the terminal half-life of R7 is about 195 minutes (3.25 hours) in mice. [2] The Tmax of R7 is about 60 minutes in mice, and its Cmax for a 78 mg/kg dose was 262 ng/mL, whereas that for a 50 mg/kg dose of tropoflavin was 70 ng/mL. [2]
Like tropoflavin, administration of R7 has been found to activate the TrkB in vivo in the mouse brain. [2] Moreover, R7 was found to potently activate the TrkB and the downstream Akt signaling pathway upon oral administration, an action that was tightly correlated with plasma concentrations of tropoflavin. [2] As such, R7 has shown in vivo efficacy as an agonist of the TrkB, including central activity, similarly to tropoflavin. [2]
Clinical data | |
---|---|
Other names | 4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(dimethylcarbamate) |
Routes of administration | By mouth [1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~35% (in mice) [2] |
Metabolites | Tropoflavin [1] |
Elimination half-life | ~3.25 hours (in mice [2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C21H20N2O6 |
Molar mass | 396.399 g·mol−1 |
3D model ( JSmol) | |
| |
|
R7 is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB) – the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF) – which is under development for the treatment of Alzheimer's disease. [1] [3] [2] It is a structural modification and prodrug of tropoflavin (7,8-DHF) with improved potency and pharmacokinetics, namely oral bioavailability and duration. [2]
R7 was synthesized by the same researchers who were involved in the discovery of tropoflavin. [2] [4] A patent was filed for R7 in 2013 and was published in 2015. [2] In 2016, it was reported to be in the preclinical stage of development. [1] [3] R7 was superseded by R13 because while R7 had a good drug profile in animals, it showed almost no conversion into tropoflavin in human liver microsomes. [5]
Tropoflavin, a naturally occurring flavonoid, was found to act as an agonist of the TrkB with nanomolar affinity (Kd ≈ 320 nM). [4]
Due to the presence of a vulnerable catechol group on its 2- phenyl-4H- chromene ring, tropoflavin is extensively conjugated via glucuronidation, sulfation, and methylation during first-pass metabolism in the liver and has a poor oral bioavailability of only 5% in mice upon oral administration. [2] As such, tropoflavin itself is a poor candidate for clinical development as an oral medication. [2] R7 is a derivative of tropoflavin with carbamate moieties on its hydroxyl groups, thereby protecting it from metabolism. [2]
As R7 is a slightly larger molecule than tropoflavin, 72.5 mg R7 is molecularly equivalent to 50 mg tropoflavin. [2] Relative to a roughly molecularly equivalent dose of tropoflavin, the area-under-curve levels of R7 were found to be 7.2-fold higher upon oral administration to mice, and R7 hence has a greatly improved oral bioavailability in mice of approximately 35%. [2] Moreover, whereas tropoflavin itself is mostly metabolized in mice within 30 minutes, tropoflavin as a metabolite was still detectable in plasma at 8 hours after administration with R7, indicating that R7 sustainably releases tropoflavin into circulation. [2] In accordance, the terminal half-life of R7 is about 195 minutes (3.25 hours) in mice. [2] The Tmax of R7 is about 60 minutes in mice, and its Cmax for a 78 mg/kg dose was 262 ng/mL, whereas that for a 50 mg/kg dose of tropoflavin was 70 ng/mL. [2]
Like tropoflavin, administration of R7 has been found to activate the TrkB in vivo in the mouse brain. [2] Moreover, R7 was found to potently activate the TrkB and the downstream Akt signaling pathway upon oral administration, an action that was tightly correlated with plasma concentrations of tropoflavin. [2] As such, R7 has shown in vivo efficacy as an agonist of the TrkB, including central activity, similarly to tropoflavin. [2]